PRME
Price
$2.71
Change
-$0.07 (-2.53%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
354.13M
50 days until earnings call
VYGR
Price
$5.04
Change
-$0.24 (-4.55%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
275.86M
55 days until earnings call
Ad is loading...

PRME vs VYGR

Header iconPRME vs VYGR Comparison
Open Charts PRME vs VYGRBanner chart's image
Prime Medicine
Price$2.71
Change-$0.07 (-2.53%)
Volume$11.38K
Capitalization354.13M
Voyager Therapeutics
Price$5.04
Change-$0.24 (-4.55%)
Volume$3.17K
Capitalization275.86M
PRME vs VYGR Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. VYGR commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a StrongBuy and VYGR is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (PRME: $2.70 vs. VYGR: $5.05)
Brand notoriety: PRME and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 54% vs. VYGR: 94%
Market capitalization -- PRME: $354.13M vs. VYGR: $275.86M
PRME [@Biotechnology] is valued at $354.13M. VYGR’s [@Biotechnology] market capitalization is $275.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileVYGR’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, VYGR is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while VYGR’s TA Score has 5 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 4 bearish.
  • VYGR’s TA Score: 5 bullish, 1 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -17.68% price change this week, while VYGR (@Biotechnology) price change was -14.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

PRME is expected to report earnings on Mar 06, 2025.

VYGR is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($354M) has a higher market cap than VYGR($276M). PRME YTD gains are higher at: -7.534 vs. VYGR (-10.935). VYGR has higher annual earnings (EBITDA): 14.1M vs. PRME (-207.13M). VYGR has more cash in the bank: 345M vs. PRME (176M). PRME has less debt than VYGR: PRME (41.2M) vs VYGR (45.3M). VYGR has higher revenues than PRME: VYGR (164M) vs PRME (800K).
PRMEVYGRPRME / VYGR
Capitalization354M276M128%
EBITDA-207.13M14.1M-1,469%
Gain YTD-7.534-10.93569%
P/E RatioN/A7.65-
Revenue800K164M0%
Total Cash176M345M51%
Total Debt41.2M45.3M91%
FUNDAMENTALS RATINGS
PRME vs VYGR: Fundamental Ratings
PRME
VYGR
OUTLOOK RATING
1..100
769
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10059
PRICE GROWTH RATING
1..100
9290
P/E GROWTH RATING
1..100
10029
SEASONALITY SCORE
1..100
58n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYGR's Valuation (41) in the Biotechnology industry is in the same range as PRME (70) in the null industry. This means that VYGR’s stock grew similarly to PRME’s over the last 12 months.

VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that VYGR’s stock grew similarly to PRME’s over the last 12 months.

VYGR's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for PRME (100) in the null industry. This means that VYGR’s stock grew somewhat faster than PRME’s over the last 12 months.

VYGR's Price Growth Rating (90) in the Biotechnology industry is in the same range as PRME (92) in the null industry. This means that VYGR’s stock grew similarly to PRME’s over the last 12 months.

VYGR's P/E Growth Rating (29) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that VYGR’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMEVYGR
RSI
ODDS (%)
Bullish Trend 7 days ago
86%
N/A
Stochastic
ODDS (%)
Bearish Trend 7 days ago
86%
Bullish Trend 7 days ago
78%
Momentum
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 7 days ago
85%
MACD
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
73%
Bearish Trend 7 days ago
86%
Advances
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
88%
Aroon
ODDS (%)
Bearish Trend 7 days ago
84%
N/A
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYGR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANTUX7.870.04
+0.51%
American Century Non-US IntrsVal Inv
JEPIX14.310.06
+0.42%
JPMorgan Equity Premium Income I
MGFLX9.48N/A
N/A
MassMutual Global Adm
APHWX10.18N/A
N/A
Artisan Value Income Institutional
AGFIX129.69-0.33
-0.25%
AB Growth I

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-2.53%
CRSP - PRME
62%
Loosely correlated
-1.26%
BEAM - PRME
60%
Loosely correlated
-8.77%
NTLA - PRME
59%
Loosely correlated
-3.13%
RXRX - PRME
55%
Loosely correlated
-6.23%
ABCL - PRME
54%
Loosely correlated
-7.67%
More

VYGR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with PLRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYGR
1D Price
Change %
VYGR100%
-4.36%
PLRX - VYGR
45%
Loosely correlated
-4.50%
RGNX - VYGR
44%
Loosely correlated
+1.44%
XENE - VYGR
40%
Loosely correlated
+3.66%
ARWR - VYGR
39%
Loosely correlated
-4.55%
AURA - VYGR
39%
Loosely correlated
+0.80%
More